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histological patterns, indicating that eTANTr, eBl, and 
MePl comprise a single biological entity. As such, future 
WHO classification schemes should consider lumping 
these variants into a single diagnostic category, such as 
embryonal tumor with multilayered rosettes (eTMr). We 
recommend combined lIN28A immunohistochemistry and 
FISH analysis of the 19q13.42 locus for molecular diag-
nosis of this tumor category. recognition of this distinct 
pediatric brain tumor entity based on the fact that the three 
histological variants are molecularly and clinically uniform 
Abstract Three histological variants are known within 
the family of embryonal rosette-forming neuroepithelial 
brain tumors. These include embryonal tumor with abun-
dant neuropil and true rosettes (eTANTr), ependymo-
blastoma (eBl), and medulloepithelioma (MePl). In this 
study, we performed a comprehensive clinical, pathologi-
cal, and molecular analysis of 97 cases of these rare brain 
neoplasms, including genome-wide DNA methylation and 
copy number profiling of 41 tumors. We identified uni-
form molecular signatures in all tumors irrespective of 
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will help to distinguish eTMr from other embryonal CNS 
tumors and to better understand the biology of these highly 
aggressive and therapy-resistant pediatric CNS malignan-
cies, possibly leading to alternate treatment strategies.
Introduction
According to the 2007 WHO classification of tumors of 
the central nervous system (CNS), CNS primitive neuro-
ectodermal tumors (PNeTs) can be further subdivided into 
CNS neuroblastoma/ganglioneuroblastoma, medulloepi-
thelioma (MePl), and ependymoblastoma (eBl) [18]. In 
addition, “embryonal tumor with abundant neuropil and 
true rosettes” (eTANTr) has been discussed as a possibly 
unique variant of CNS PNeT [1, 2, 4, 6, 8, 10, 11, 19].
CNS neuroblastomas histologically and molecularly 
resemble subsets of medulloblastomas and peripheral neu-
roblastomas [18]. They are characterized by the presence 
of Homer Wright (neuroblastic) rosettes, foci of neuro-
cytic and/or ganglion cell maturation, intense synaptophy-
sin expression, and MYC/MYCN amplifications in almost 
50 % of cases [3, 18]. On the other hand, eTANTr, eBl, 
and MePl are rare neoplasms characterized by the pres-
ence of similar histological patterns, namely multilayered 
and pseudo-stratified rosette-forming structures of variable 
shape and size. Both eBl and eTANTr include the so-
called “ependymoblastic rosettes” harboring well-formed 
central round or slit-like lumina in the absence of an outer 
membrane [4, 6, 11, 12, 14, 18]. MePl is histologically 
characterized by papillary and tubular structures sur-
rounded by an external limiting membrane, reminiscent 
of the developing neural tube [4, 18]. These structures are 
sometimes also referred to as “medulloepithelial” rosettes. 
Moreover, some MePl have also been reported to display 
ependymoblastic rosettes [18]. These three variants of 
embryonal CNS tumors show a clinically uniform behavior, 
in that they predominantly affect infants under the age of 
4 years and are associated with a highly aggressive course 
with reported survival times up to 24–36 months, but typi-
cally averaging 12 months [1, 5, 9, 11, 15, 23].
Applying FISH analysis, we previously found amplifi-
cations at 19q13.42 involving the C19MC cluster in 93 % 
of tumors diagnosed either as eTANTr, eBl, or MePl 
with eTANTr features, but not in any other pediatric brain 
tumors [15]. These results demonstrate that this genetic 
aberration is highly sensitive and specific to embryonal 
CNS tumors with multilayered rosettes irrespective of 
other features and that these subtypes are highly interre-
lated. recently, Paulus and Kleihues therefore proposed to 
use the term “embryonal tumor with multilayered rosettes” 
(eTMr) as a general name for these tumors, a new entity, 
in part defined by the C19MC amplification itself [22].
To further test whether the three histological variants 
of eTMr represent a single entity, we performed clinico-
pathological and molecular analyses in 97 eTMr samples 
initially designated as eTANTr, eBl, or MePl.
Materials and methods
Ninety-seven diagnostic specimens diagnosed histopatho-
logically as either eTANTr, eBl, or MePl were received 
for this study from various sources around the globe and 
collected during the last 5 years. Among these sources were 
Burdenko Neurosurgical Institute, Moscow, russia; Uni-
versity of Bonn, germany; ludwig-Maximilians Univer-
sity, Munich, germany; University of Münster, germany; 
University of Tübingen, germany; Università Sapienza, 
rome, Italy; Necker Hospital, Paris, France; Academic 
Medical Center, Amsterdam, the Netherlands; University 
of Cambridge, Cambridge, UK; Institute of Neurology, 
Vienna, Austria; Hospital for Sick Children, Toronto, Can-
ada; Memorial Sloan Kettering Cancer Center, New York, 
USA; and University of California, San Francisco, USA. A 
subset of these cases was previously published [15, 16].
All cases were routinely formalin fixed and paraffin 
embedded. For diagnostic purposes, routine histopathologi-
cal examination and immunohistochemical (IHC) analyses 
were performed in the different institutions participating in 
this study. Further centralized evaluation of all H&e slides 
was performed in the Heidelberg University Department 
of Neuropathology. In all 97 cases, IHC analysis applying 
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a lIN28A polyclonal antibody and FISH analysis for the 
19q13.42 locus were performed as previously described 
[15, 16].
For samples for which sufficient DNA was available 
(n = 41), we analyzed copy number aberrations (CNAs) 
using data generated with Illumina Human Methylation 
450 k BeadChip arrays as described previously [13, 26]. 
For the detection of amplifications, chromosomal gains and 
losses, automatic scoring was verified by manual assess-
ment of the respective loci for each individual profile as 
previously described [26].
To evaluate the molecular specificity of potential eTMr 
subtypes, we performed comparative cluster analysis of 
450 k profiles generated for 41 eTMr together with 110 
other primary pediatric brain tumors including pilocytic 
astrocytoma (PA; n = 10), ependymoma (ePN; n = 10), 
glioblastoma grade IV (gBM; n = 40), atypical teratoid 
rhabdoid tumor (AT/rT; n = 10), and medulloblastoma 
(MB; n = 40). eight normal cerebellum (CBM) samples 
were also included. The following criteria were applied 
to filter the data: removal of probes targeting the X and Y 
chromosomes (n = 11,551), removal of probes contain-
ing a single-nucleotide polymorphism (dbSNP132 Com-
mon) within five base pairs of and including the targeted 
Cpg-site (n = 24,536), and probes not mapping uniquely 
to the human reference genome (hg19) allowing for one 
mismatch (n = 9,993). In total, 438,370 probes were kept 
for analysis. For unsupervised hierarchical clustering of 
41 eTMr samples, we selected the 4,756 most variably 
methylated probes across the dataset (s.d. >0.25). Samples 
were clustered using 1-Pearson correlation coefficient as 
the distance measure and average linkage (x-axis). Meth-
ylation probes were reordered by hierarchical clustering 
using euclidean distance and average linkage (y-axis). The 
heatmap illustration of 41 eTMr samples and 118 other 
pediatric brain tumor and control samples was generated by 
separately determining the 2,500 most variably methylated 
probes between the medulloblastoma subgroups, the K27-, 
g34-, IDH-, and wt (not H3.3 or IDH mutated) gBM sub-
groups, the non-eTMr tumor samples, and across the 
whole dataset. Probes were only used once (n = 6,540). 
Methylation probes were reordered by hierarchical cluster-
ing using euclidean distance and average linkage (y-axis).
Results
Pathological examination of the eTMr cohort
According to published histopathological criteria, the 97 
eTMr cases studied were diagnosed as eTANTr (55 
cases), eBl (34 cases), or MePl (eight cases) after cen-
tral review. eTANTr was defined according to the criteria 
previously described by eberhart et al. [6]. These tumors 
showed a biphasic pattern featuring highly cellular clusters 
of small cells with round or polygonal nuclei and scanty 
cytoplasm admixed with large fibrillar and paucicellu-
lar neuropil-like areas, infrequently containing neoplastic 
neurons. Among the clusters and aggregates of small cells, 
numerous true multilayered ependymoblastic rosettes were 
identified (Fig. 1a). In some cases, these rosettes were 
observed abruptly in the neuropil areas and neoplastic neu-
rons were found between the cells composing layers of the 
rosettes. eBl and MePl were diagnosed according to cur-
rent WHO classification criteria [18]. eBl was identified 
as a tumor with the exclusive presence of nests and clus-
ters of poorly differentiated cells forming true multilayered 
ependymoblastic rosettes but lacking a neuropil-like matrix 
(Fig. 1d). These rosettes were intermixed with small to 
medium-sized primitive cells having a high nucleus/cyto-
plasm ratio and variably developed fibrillary processes. 
MePl was characterized by the presence of papillary, tubu-
lar, and/or trabecular arrangements of neoplastic pseudo-
stratified epithelium with an outer membrane resembling 
the primitive neural tube (Fig. 1g). In zones distinct from 
tubular structures, large areas of poorly differentiated cells 
including collections of true multilayered ependymoblastic 
rosettes were found in all eight cases studied.
recently, we have shown that expression of lIN28A is a 
highly specific and sensitive marker for pathological verifi-
cation of eTMr [16, 23]. In the present series, strong and 
diffuse lIN28A cytoplasmic immunostaining was found in 
all 97 tumors studied irrespective of their histopathological 
appearance mentioned above (Fig. 1c, f, i). lIN28A posi-
tivity was found to be more prominent and intense in mul-
tilayered rosettes and poorly differentiated small-cell tumor 
areas of eTANTr/eBl, and in papillary and tubular struc-
tures of MePl.
Pathological analysis of recurrent eTMr samples
We were able to perform histological and molecular anal-
ysis of 14 samples obtained from local recurrences of 
eTMr: 11 were initially diagnosed as eTANTr, two as 
eBl, and one as MePl. In addition, three samples from 
extracranial metastases of eTANTr (one in cranial soft tis-
sue and two in the peritoneal cavity) were analyzed.
Upon secondary surgery at the time of relapse, histopa-
thology in all 11 eTANTr samples showed a loss of neu-
ropil-like foci. The secondary biopsy specimens obtained 
from nine eTANTrs disclosed extended collections of 
multilayered rosettes with various size and shape reflecting 
a histological pattern compatible with eBl (Fig. 2a, b). The 
other two samples showed prominent papillary and tubu-
lar structures, closely resembling MePl (Fig. 2c, d). The 
extracranial metastasis of one eTANTr was predominantly 
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composed of clusters of ependymoblastic rosettes varying 
in shape and size. In two other eTANTr metastases, papil-
lary and tubular “MePl-like” structures were detected. The 
two recurrent eBl samples and one MePl showed histo-
pathological features reminiscent of the corresponding pri-
mary tumors.
Immunohistochemical expression of the eTMr marker 
lIN28A was retained in all recurrent tumor samples and the 
number of positively stained cells in recurrent eTANTrs 
was higher in comparison to their primaries [16].
Clinical parameters do not differ between the three eTMr 
groups
Basic clinical characteristics from all 97 patients included 
in this study are summarized in Table 1. All tumors 
occurred in very young children: range 0.5–6 years 
(median 2.3 years), and only eight patients (8 %) were 
older than 3 years. The male:female ratio was 1.1:1. The 
mean age for the three histological variants of eTMr did 
not differ significantly. Most tumors (64 cases; 70 %) were 
located supratentorially, with almost half of these (n = 30) 
found in the fronto-parietal region. Infratentorial location 
was less frequent (27 cases; 30 %) affecting either the cer-
ebellum (n = 10) or brain-stem (n = 17). exact informa-
tion about tumor location was not available for six patients. 
Supra- and infratentorial location within the three eTMr 
groups did not differ significantly (Table 1). Data on meta-
static stage at tumor diagnosis were available for only 32 
patients. Most presented with M0 disease (26/32, 80 %), 
two with M2 stage, and four with M3 stage.
Details of patient treatment were known for 36 patients 
(18 eTANTr; 14 eBl, and 4 MePl). Sixteen patients 
had undergone gross total tumor resection, while for the 
other 20 children only subtotal tumor removal could be 
achieved. Only three patients received postoperative 
cranio-spinal irradiation, whereas all 36 patients were 












Fig. 1  Microscopical appearance (a, d, g), FISH analysis of the 
19q13.42 locus (b, e, h), lIN28A immunohistochemistry (c, f, i) 
of eTANTr (a–c), eBl (d–f) and MePl (g–i). Amplification of 
19q13.42 (b, e, h) and lIN28A immunoexpression (c, f, i) was 
detected in all three histological eTMr subtypes. For the FISH 
analysis the C19MC 19q13.42 probe (green signals) and a reference 
19p13 probe were used (red signals)
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protocol [9]. Follow-up data were available for 55 
patients demonstrating that 50 tumors recurred during 
follow-up with a median progression-free survival (PFS) 
of 8 months, and 84 % (46/55) of patients died within 
3 years after their initial diagnosis. Median overall sur-
vival (OS) was 12.3 months and did not differ signifi-
cantly between the three histological variants of eTMr 
(log-rank; p = 0.63, Fig. 3). Only two patients with an 
initial histological diagnosis of eTANTr are still alive 
more than 4 years after the first intervention (57 and 
68 months, respectively).
Patterns of disease progression were highly variable. 
Most of the patients experienced local tumor regrowth as 
a first recurrence pattern, whereas a smaller number devel-
oped widespread leptomeningeal metastatic dissemination, 
very often after intervention on the recurrent lesion. Four 
patients additionally showed systemic metastases outside 
of the CNS in the cranial soft tissue, as well as pleural and 
peritoneal cavities.
Fig. 2  Two examples of 
primary eTANTr (a, c) with 
further tumor transformation 
in either eBl (b) or MePl 
(d) histology as it has been 












 Median 2.5 2.6 2.2
 range 1–5 0.5–6 1–3
gender
 Male 29 15 3
 Female 26 19 5
Tumor location
 Supratentorial 37 21 6
 Infratentorial 14 11 2
events
 recurrence 29/32 16/17 5/6
 Death 26/32 14/17 5/6
Survival
 Median PFS (months) 9.3 7.1 7.3
























Fig. 3  Overall survival curves generated for eTANTr (32 cases, 
blue), eBl (17 cases, red), and MePl (6 cases, green). No differ-
ences in survival time were found (log-rank, p = 0.63)
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Fig. 4  Cluster analyses of DNA methylation profiles of eTMr 
alone and compared to various other pediatric brain tumors and nor-
mal cerebellum. a Unsupervised cluster analysis of eTMr samples 
only shows that DNA methylation profiles of the histological variants 
eTANTr, eBl and MePl are not distinct. Also, clusters outlined do 
not differ in terms of clinical findings, including age, gender, tumor 
location and outcome. b DNA methylation profiles of eTMrs are 
distinct from other pediatric brain tumors and normal cerebellum
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Cytogenetic analysis of 19q13.42 locus in eTMr
All 97 tumor samples were analyzed by FISH for 
amplification of the 19q13.42 locus. A high-level focal 
amplification of this locus (present in 40–80 % of tumor 
nuclei) was detected in 93 samples (96 %) (Fig. 1b, e, h). 
The four remaining tumors (two diagnosed as eTANTr 
and two as eBl) displayed polysomy 19, i.e., a low-level 
Table 2  Copy number aberrations in 41 eTMr cases
ETANTR embryonal tumor with abundant neuropil and true rosettes, EBL ependymoblastoma, MEPL medulloepithelioma, DOD died of disease, 
POD alive, progression of disease, NED alive, no evidence of disease, NA not available
N Age (years) gender location Histology Amplification gains losses Outcome
1 2 F Supra eTANTr 19ql3.42 2 No DOD (21 m)
2 2 M Supra eTANTr 19ql3.42 7 6q NeD (57 m)
3 3 F Supra eTANTr 19ql3.42 2 19q DOD (18 m)
4 2 M Infra eTANTr 19ql3.42 2 No DOD (l0 m)
5 1 F Infra eTANTr No lq, 19p No DOD (32 m)
6 2 M Supra eTANTr 19ql3.42 2, 14, 17, 20 No D0D (12 m)
7 3 F Supra eTANTr 19ql3.42 2 No DOD (15 m)
8 2 M Supra eTANTr 19ql3.42 2 No DOD (10 m)
9 2 F Infra eTANTr 19ql3.42 7, llq 6q, 9, 12q, 16 DOD (23 m)
10 3 F Supra eTANTr 19ql3.42 2, 7, 11 6q, 19q DOD (10 m)
11 3 M Infra eTANTr 19ql3.42 2, 4, 7, llq lp, 19q DOD (10 m)
12 2 F Supra eTANTr 19ql3.42 2, 21q No DOD (12 m)
13 3 M Supra eTANTr 19ql3.42 2, 16 No DOD (11 m)
14 2 F Supra eTANTr 19ql3.42 No 6q DOD (12 m)
15 3 M Supra eTANTr 19ql3.42 2 No POD (6 m)
16 2 F Supra eTANTr 19ql3.42 2 No NA
17 3 M Supra eTANTr 19ql3.42 2 No DOD (14 m)
18 3 F Supra eTANTr 19ql3.42 No 7q NA
19 2 M Supra eTANTr 19ql3.42 lq, 2, 4, 7q, 12q, 13q, 21q 8q, l0q POD (4 m)
20 5 M Infra eTANTr 19ql3.42 2, 11 No DOD (9 m)
21 2 M Supra eTANTr 19ql3.42 lq, 2, 6p, 7, llq, 21q lp, lip, 18p, 22q DOD (7 m)
22 3 F Supra eTANTr 19ql3.42 lq, 2, 4, 7, 8, 11, 16, 17, 20, 21q No NeD (68 m)
23 2 M Supra eTANTr 19ql3.42 2, 15q No DOD (9 m)
24 2 F Supra eBl 19ql3.42 2, 3, 4, 7, 8, 13q No DOD (10 m)
25 2 F Supra eBl 19ql3.42 llq lp, 19q, 22q DOD (12 m)
26 3 M Supra eBl 19ql3.42 lq, 7 6q, 19q DOD (10 m)
27 2 M Supra eBl 19ql3.42 6p, 7 No DOD (10 m)
28 2 F Supra eBl 19ql3.42 lq, 2, 3q, 4 No DOD (11 m)
29 2 M Supra eBl 19ql3.42 2 6q, 17p DOD (6 m)
30 2 M Infra eBl No lq, 2, 17q No DOD (9 m)
31 3 F Supra eBl 19ql3.42 2 No NeD (6 m)
32 3 F Infra eBl 19ql3.42 2, 19, 20, 21q No NA
33 2 F Supra eBl 19ql3.42 2, 5q, 7, llq, 15q, 21q 22q POD (11)
34 3 M Supra eBl 19ql3.42 lq, 2, 6p, 17, 20q 6q, 14q, 19q POD (21 m)
35 2 F Supra eBl 19ql3.42 No 19q NA
36 3 M Supra MePl 19ql3.42 2, 5p, llq, 17q, 20q lp, 6q, 12p, 19q DOD (6 m)
37 2 M Supra MePl 19ql3.42 2, 17, 19 No DOD (5 m)
38 1 F Supra MePl 19ql3.42 2 No DOD (7 m)
39 NA NA NA NA 19ql3.42 2 No NA
40 NA NA NA NA 19ql3.42 2 No NA
41 NA NA NA NA 19ql3.42 2, 7q, 8 No NA
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gain of both the target locus and the reference locus, 
compatible with an aberration affecting large parts of 
the chromosome or with an overall state of polyploidy. 
FISH analysis of the 14 recurrent tumors showed that 
the 19q13.42 amplification was retained in all samples. 
Moreover, the number of nuclei with amplification was 
significantly higher in secondary lesions (up to 100 % of 
nuclei) in comparison to their matched primary tumors 
[15].
DNA copy number analysis and methylation profiling 
of eTMr
Next, we analyzed the genome-wide DNA methyla-
tion profiles of 41 eTMr samples using the Illumina 
450 k DNA methylation arrays. As shown previously 
for glioblastoma and medulloblastoma [13, 26], DNA 
methylation profiling provides an excellent tool for the 
molecular sub-classification of distinct tumor entities. 
Unsupervised clustering analysis of the methylation 
data of the 41 eTMr samples did not reveal subgroup-
ing according to eTMr histological subtypes (Fig. 4a). 
However, comparison to a large cohort of other pediatric 
brain tumors (n = 110) revealed that eTMrs are clearly 
distinct from other CNS tumors (Fig. 4b). In addition, 
data generated from these arrays can be used to detect 
CNAs in individual tumor samples. All CNAs detected 
from the methylation arrays for these 23 eTANTr, 12 
eBl, 3 MePl, and 3 additional histologically unidenti-
fied cases are outlined in Table 2. Amplification of the 
19q13.42 locus was confirmed for 39/41 (95 %) primary 
tumors examined. Only one eTANTr and one eBl 
showed no amplification confirming the FISH analyses 
in these two samples. No other genomic amplifications 
were detected in this series of primary eTMr. Other 
recurrent low-level CNAs in these tumors included gain 
of chromosome 2 in 31 cases (76 %), gain of 7q (12/41, 
29 %), gain of 11q (9/41, 22 %), gain of 1q (8/41, 20 %), 
and loss of 6q in eight cases (20 %). In eight cases, we 
additionally identified a focal genomic loss at 19q13.2–
13.3, i.e., centromeric to the C19MC amplified region, 
suggesting complex intra-chromosomal rearrangements 
on the 19q13 locus in a subset of eTMr. No significant 
differences in the frequency of any of these CNAs were 
detected between the three histological eTMr variants 
(Fig. 5).
Discussion
Currently, the verification of a distinct nosologic posi-
tion for various human malignancies is complemented (or 
sometimes defined) by a comprehensive molecular work-
up [23, 26]. A number of refinements have recently been 
introduced into the current histological classification of 
pediatric CNS tumors. For example, the routine applica-
tion of molecular diagnostics distinguishes AT/rTs from 
other PNeTs [18] and current studies strongly suggest 
incorporating four molecular medulloblastoma subgroups 
into the classification as separate tumor entities [20]. These 
molecular data will help to further subdivide existing tumor 
entities by identifying disease variants with diverse clini-
cal outcomes, distinct biology and clues regarding cell of 
origin. In contrast, molecular analyses of a representative 
cohort of eTANTr, eBl, and MePl, three rare variants 
of embryonal CNS neoplasms, strongly suggests their 
integration into one single tumor entity called eTMr. All 
tumors were positive for lIN28A, a marker highly specific 
for eTMrs, and almost all cases displayed amplification 
of the C19MC mirNA cluster at 19q13.42, as well as fre-
quent trisomy 2. Furthermore, no significant differences in 
other CNAs were observed between these three histological 
variants and their DNA methylation patterns were highly 
concordant.
Morphologically, eTMr manifests uniformly with the 
presence of multilayered true rosettes: “ependymoblastic” 
and/or “medulloepithelial”, with variable shape and size. 
As already noted, it may frequently be difficult to distin-
guish between eBl and MePl [18]. Diagnostic differences 
between these tumor categories are descriptive and concep-
tual because they are, in general, based only on the absence 
of an outer collagen IV-positive membrane and apical cyto-
plasmic blebs in eBl structures. Moreover, similar clinical 
parameters and a highly aggressive course of disease for all 
eTMr histological variants (resistance to treatment, inevi-
table tumor recurrence and rapid death) also support our 
suggestion of commonality [1, 8, 9, 11, 15, 16, 19].
Previously, molecular analysis of various eTMr sub-
types has been hampered by limited cohort sizes and to 
date, only a few chromosomal imbalances were detected by 
conventional CgH analysis [7, 25]. recently, we described 
a focal unique amplicon at 19q13.42 spanning 0.89 Mb 
and covering the C19MC genomic locus, the largest known 
cluster of human microrNA-coding genes [24]. Further, 
the C19MC locus was found to be amplified in 93 % of 
eTMr diagnosed previously on the basis of their char-
acteristic morphology [15], and these findings have been 
confirmed by others [5, 17, 21, 23, 27, 28]. Thus, C19MC 
amplification is a highly specific genetic eTMr hallmark, 
similar to loss of the SMARCB1 locus in AT/rT or t(11;22) 
in ewing sarcoma [18]. This suggests that the C19MC 
Fig. 5  Copy number plots generated from 450 k methylation data. 
Amplifications and gains are indicated in green, losses in red. a 
example of an eTANTr showing amplification 19q13.42, gain of 
2 and loss of 19q13.3. b example of an eBl showing amplification 
19q13.42, gain of 2, and losses of 6q and 17p. c example of a MePl 
showing amplification 19q13.42, trisomy of 2, 17 and 19. d Summa-
rizing profiles for all 41 cases analyzed
◂
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amplification could serve as a “driver” oncogenic event in 
eTMr. Comprehensive analysis of CNAs in our eTMr 
cohort revealed few other recurrent chromosomal gains and 
losses, and no subtle cytogenetic differences between the 
tumors with various histological features could be defined.
Common molecular signatures between the three his-
tological variants of eTMr suggest that they may share a 
common origin, such as a primitive cell population in the 
subependymal region, with further evolution into a wide 
range of morphological appearances and mimics. In support 
of this suggestion, analysis of the 11 recurrent eTANTr 
samples revealed its frequent histological evolution into 
either eBl or MePl phenotypes, while at the same time 
the molecular genetic make-up did not change between the 
initial and advanced stages of disease. Such stepwise mor-
phologic transformations in the “classic” eTANTr appear-
ance due to disease progression allow one to suppose that 
the three “histological variants” of eTMr may constitute 
either “polar ends” of a morphologic spectrum or varying 
differentiation stages of a single tumor entity rather than 
separate nosologic categories.
In conclusion, we identified uniform molecular signa-
tures occurring in a representative subset of embryonal brain 
tumors with multilayered rosettes indicating that eTANTr, 
eBl, and MePl comprise a single biological entity, which 
could potentially be designated in future WHO schemes 
as eTMr. For molecular diagnosis of this tumor category 
and to distinguish them from other embryonal tumors of 
the CNS, combined lIN28A IHC and FISH analysis of 
the 19q13.42 locus are recommended as routine diagnostic 
markers. Since misdiagnosis for controversial “poorly dif-
ferentiated” embryonal CNS neoplasms is not uncommon, 
all tumors and especially CNS-PNeTs harboring combined 
lIN28 expression and 19q13.42 amplification should be 
classified as eTMr, even in absence of the key histological 
patterns. As a next step, it will be important to understand 
the distinct biological significance of the prototypic molecu-
lar events in eTMr which may provide therapeutic targets 
for novel treatment strategies for these highly aggressive 
and therapy-resistant pediatric CNS malignances.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
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